REGENXBIO (RGNX) will hold an investor event on October 20, 2026, at 1:00 PM ET in New York and via webcast. The event will cover the sura-vec clinical program, including the ATMOSPHERE and ASCENT pivotal trials, with perspectives from retina specialists. Topline pivotal data is anticipated in Q4 2026.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
